We attended the Citi European Healthcare Tour with company and physician meetings in the UK, Switzerland and France. Our take: Immuno-oncology (I/O) hopes becomes reality, faster and broader than ever thought.
2016 will be the year of immune-oncology combinations, the potentially holy grail of this space. The I/O field develops extremely fast and what looked promising yesterday can be redundant tomorrow and vice versa.
Big, early players with broad approaches and capabilities look the most promising. Pricing of I/O agents especially in Europe is going to determine the rate of adoption.
Rarely are health inequalities more apparent than when walking around San Francisco during the J.P. Morgan Healthcare Conference. In our chart of the month, Raphael Oesch (Portfolio Manager), takes a look at the statistics and discusses some of the reasons behind the figures.
We recently attended the 41st J.P. Morgan Healthcare Conference in San Francisco, which took place from January 9th to January 12th 2023. Our overall conclusion from the conference is that the industry remains in good shape. The key themes that emerged during the week from a devices and services perspective were, the rise of value-based care and innovation & digitalisation. However, it also became clear that the macroeconomic environment is still the dominant force behind (sub) sector performance.
Day after day currently feels like a roller coaster ride, going up because of better than hoped for CPI numbers, down because of looming recession fears, and back up because of a less hawkish FED speech. Are we there yet? What do you think?